TNSN01036A1 - 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES - Google Patents
5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASESInfo
- Publication number
- TNSN01036A1 TNSN01036A1 TNTNSN01036A TNSN01036A TNSN01036A1 TN SN01036 A1 TNSN01036 A1 TN SN01036A1 TN TNSN01036 A TNTNSN01036 A TN TNSN01036A TN SN01036 A TNSN01036 A TN SN01036A TN SN01036 A1 TNSN01036 A1 TN SN01036A1
- Authority
- TN
- Tunisia
- Prior art keywords
- lower alkyl
- mqr4
- co2r4
- halogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DISCLOSED ARE COMPOUNDS OF THE FORMULA WHERE IN : R2 IS HYDROGEN, ALKYL, OR CYCLOALKYL ; R3 IS HYDROGEN, LOWER ALKYL, LOWER ALKOXY, HALOGEN, TRIFLUOROMETHYL, LOWER ALKYNYL, LOWER ALKENYL, NITRILE, NITRO, -COR4, -CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), Y IS N OR CR7 ; R9 IS LOWER ALKYL, HALOALKYL, OR ARYL ; X AND Z ARE INDEPENDENTLY HYDROGEN, HALOGEN, LOWER ALKYL, LOWER ALKOXY,TRIFLUOROMETHYL, HYDROXY, NITRILE, NITRO, -NR4R5, -N(O)R4R5, -NR4R5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mQR4, OR –NR4C(O)T(CH2)mQR5 ; m IS 1 TO 6 ; T IS O, S, NR4, N(O)R4, NR4R5W, OR CR4R5 ; Q IS O, S, NR4, N(O)R4, NR4R5W, CO2, OR A CARBOCYCLIC GROUP CONTAINING FROM 3 TO 7 MEMBERS, UP TO FOUR OF WHICH MEMBERS ARE OPTIONALLY HETEROATOMS INDEPENDENTLY SELECTED FROM OXYGEN, SULFUR, AND NITROGEN, WHEREIN THE CARBOCYCLIC GROUP IS UNSUBSTITUTED OR SUBSTITUTED WITH ONE, TWO, OR THREE GROUPS INDEPENDENTLY SELECTED FROM HALOGEN, HYDROXY, HYDROXYALKYL, LOWER ALKYL, LOWER ALKOXY ALKOXYCARBONYL, ALKYLCARBONYL, ALKYLCARBONYLAMINO, AMINOALKYL, TRIFLUOROMETHYL, N-HYDROXYACETAMIDE, TRIFLUOROMETHYLALKYL, AMINO, OR MONO OR DIALKYLAMINO ; R6 LOWER ALYL, HALOALKYL OR ARYL; R7 IS –NR4R5, -N(O)R4R5, -NR4R5R9X, -OH, -OR4, -SR4, HALO, -COR4, (CH2)nR4, CO2R4, CONR4R5, -C(O)NR4SO2R5, -S(O)R4, -SO2R4, -SO2NR4R5, -SO3R4, -(CH2)nP(O)(OR4)2, -NR4SO2R5, ALDEHYDE, NITRILE, NITRO, ALKYL ALKOXYALKYL, -T(CH2)mQR4, -C(O)T(CH2)mQR4, -NR4C(O)T(CH2)mQR5, OR –T(CH2)CO2R4 ; n IS 0 TO 6 ; W IS AN ANION ; R4 AND R5 ARE INDEPENDENTLY HYDROGEN, LOWER ALKYL, LOWER ALKENYL, LOWER ALKYNYL, (CH2) nAr, ARYLALKYL, ARYL, HETEROARYL, HETEROARYLALKYL, CYCLOALKYL, HETEROCYCLOALKYL, OR HETEROARYL, OR R4 AND R5 TOGETHER WITH THE NITROGEN TO WHICH THEY ARE ATTACHED FORM A CARBOCYCLIC RING CONTAINING 3 TO 8 MEMBERS, UP TO FOUR OF WHICH MEMBERS ARE OPTIONALLY CARBONYL GROUPS OR HETEROATOMS INDEPENDENTLY SELECTED FROM O, S, SO, S(O)2, AND N; AND WHEN Y IS CR7 , IT IS PART OF THE PORT STRUCTURE …….. WHEREIN R7 AND Z ARE AS DEFINED ABOVE, OR CAN BE TAKEN TOGETHER WITH THE CARBONS TO WHICH THEY ARE ATTACHED TO FORM… WHEREIN : G AND J ARE INDEPENDENTLY CH2, NH, OR O; B IS NH, S, CH2, OR O; D IS C OR N, PROVIDED THAT R10 IS NOTHING WHEN D IS N; AND R10 AND R11 ARE INDEPENDENTLY HYDROGEN, HALOGEN, LOWER ALKYL, LOWER ALKOXY, OR ALKYLCARBONYL; THESE COMPOUNDS ARE USEFUL FOR TREATING CELL PROLIFERATIVE DISORDERS, SUCH AS CANCER, ATHEROSCLEROSIS, AND RESTENOSIS. THESE COMPOUNDS ARE POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) AND GROWTH FACTOR-MEDIATED KINASES; THE PRESENT INVENTION ALSO PROVIDES A METHOD OF TREATING CELL PROLIFERATIVE DISORDERS; ALSO PROVIDED BY THE PRESENT INVENTION IS A PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND OF FORMULA I TOGETHER WITH A CARRIER OR EXCIPIENT
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18712400P | 2000-03-06 | 2000-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN01036A1 true TNSN01036A1 (en) | 2005-11-10 |
Family
ID=22687699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN01036A TNSN01036A1 (en) | 2000-03-06 | 2001-03-02 | 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1268476A1 (en) |
| JP (1) | JP2003528101A (en) |
| KR (1) | KR20020075805A (en) |
| CN (1) | CN1422268A (en) |
| AP (1) | AP2002002643A0 (en) |
| AR (1) | AR034119A1 (en) |
| AU (1) | AU2001233028A1 (en) |
| BG (1) | BG107161A (en) |
| BR (1) | BR0109056A (en) |
| CA (1) | CA2401368A1 (en) |
| CO (1) | CO5280200A1 (en) |
| CR (1) | CR6736A (en) |
| CZ (1) | CZ20022929A3 (en) |
| DZ (1) | DZ3308A1 (en) |
| EA (1) | EA200200802A1 (en) |
| EE (1) | EE200200506A (en) |
| GT (1) | GT200100037A (en) |
| HN (1) | HN2001000040A (en) |
| HR (1) | HRP20020798A2 (en) |
| HU (1) | HUP0300136A2 (en) |
| IL (1) | IL151480A0 (en) |
| IS (1) | IS6524A (en) |
| MA (1) | MA26881A1 (en) |
| MX (1) | MXPA02008535A (en) |
| NO (1) | NO20024235L (en) |
| NZ (1) | NZ520962A (en) |
| OA (1) | OA12227A (en) |
| PA (1) | PA8513201A1 (en) |
| PE (1) | PE20011177A1 (en) |
| PL (1) | PL358271A1 (en) |
| SK (1) | SK12472002A3 (en) |
| SV (1) | SV2001000338A (en) |
| TN (1) | TNSN01036A1 (en) |
| WO (1) | WO2001070741A1 (en) |
| YU (1) | YU66502A (en) |
| ZA (1) | ZA200207110B (en) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| MXPA03003612A (en) | 2000-10-23 | 2003-06-19 | Smithkline Beecham Corp | Novel compounds. |
| KR100639772B1 (en) * | 2001-02-12 | 2006-10-30 | 에프. 호프만-라 로슈 아게 | 6-substituted pyrido-pyrimidines |
| WO2002068419A1 (en) | 2001-02-26 | 2002-09-06 | Tanabe Seiyaku Co., Ltd. | Pyridopyrimidine or naphthyridine derivative |
| US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
| US20030100572A1 (en) * | 2001-06-21 | 2003-05-29 | Ariad Pharmaceuticals,Inc. | Novel pyridopyrimidones and uses thereof |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| CN1646131A (en) | 2002-04-19 | 2005-07-27 | 史密丝克莱恩比彻姆公司 | Novel compounds |
| WO2004011456A1 (en) | 2002-07-31 | 2004-02-05 | Danter Wayne R | Protein tyrosine kinase inhibitors |
| US7629347B2 (en) | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| BRPI0406809A (en) * | 2003-01-17 | 2005-12-27 | Warner Lambert Co | 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| EP1663204B1 (en) * | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| DK1685131T3 (en) | 2003-11-13 | 2007-07-09 | Hoffmann La Roche | Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones |
| DE102004029784A1 (en) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
| DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
| FR2873118B1 (en) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (en) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
| CA2575804A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| DE102004058337A1 (en) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
| EP1856053A1 (en) | 2005-01-14 | 2007-11-21 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| EP1868612A4 (en) | 2005-03-25 | 2010-03-24 | Glaxo Group Ltd | Novel compounds |
| PE20061193A1 (en) | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38 |
| WO2006104917A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
| AR053346A1 (en) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38 |
| US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| FR2887882B1 (en) | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
| EP1931670B1 (en) | 2005-10-07 | 2012-09-12 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k |
| EP2322523B1 (en) * | 2005-10-07 | 2019-01-02 | Exelixis, Inc. | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha |
| FR2896246B1 (en) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| PL2074122T3 (en) | 2006-09-15 | 2011-10-31 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| BRPI0715566A2 (en) * | 2006-10-16 | 2013-07-02 | Gpc Biotech Inc | compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound |
| WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| FR2910813B1 (en) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA |
| US8138181B2 (en) * | 2007-04-03 | 2012-03-20 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| RU2010101052A (en) * | 2007-06-15 | 2011-07-20 | Банью Фармасьютикал Ко., Лтд (Jp) | Bicycloaniline derivatives |
| EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| EP2231656A1 (en) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| CA2719538C (en) | 2008-04-07 | 2014-03-18 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| UY32153A (en) | 2008-09-30 | 2011-04-29 | Exelixis Inc | PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| EP2486037A4 (en) * | 2009-10-09 | 2013-01-16 | Afraxis Inc | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| US8889696B2 (en) | 2009-12-18 | 2014-11-18 | Temple University—Of the Commonwealth System of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof |
| UY33221A (en) | 2010-02-09 | 2011-09-30 | Univ California | METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| KR101434841B1 (en) * | 2010-08-05 | 2014-08-29 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| EP2646448B1 (en) | 2010-11-29 | 2017-08-30 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| PT2710005T (en) * | 2011-05-17 | 2016-11-16 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
| CN104271576A (en) * | 2012-02-23 | 2015-01-07 | 艾伯维公司 | Pyridopyrimidinone inhibitors of kinases |
| MX363715B (en) * | 2013-02-21 | 2019-03-29 | Pfizer | Solid forms of a selective cdk4/6 inhibitor. |
| EP3024464A1 (en) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Treatment of myelodysplastic syndrome |
| WO2016015597A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| TWI646094B (en) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| MA45920B1 (en) | 2016-08-15 | 2021-08-31 | Pfizer | Pyridopyrimidinone cdk2 / 4/6 inhibitors |
| KR102583737B1 (en) * | 2017-03-03 | 2023-09-26 | 오클랜드 유니서비시즈 리미티드 | FGFR Kinase Inhibitors and Pharmaceutical Uses |
| BR112020015431A2 (en) | 2018-02-15 | 2020-12-08 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS |
| TW202035406A (en) * | 2018-12-07 | 2020-10-01 | 大陸商杭州英創醫藥科技有限公司 | Heterocyclic compound as CDK-HDAC dual pathway inhibitor |
| CN112759589B (en) * | 2019-11-01 | 2022-04-08 | 暨南大学 | Pyrimidopyridinones and their use |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| KR20230148235A (en) * | 2021-03-08 | 2023-10-24 | 지난 유니버시티 | Pyridopyrimidine compounds and their applications |
| WO2024056091A1 (en) * | 2022-09-16 | 2024-03-21 | 华东师范大学 | Pyridonopyrimidine derivative as rsk inhibitor and use thereof |
| WO2024099403A1 (en) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP0964864B1 (en) * | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| ES2310039T3 (en) * | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | BICYCLE PYRIMIDINES AND BICYCLE 3,4-DIHYDROPIRIMIDINS AS INHIBITORS OF CELL PROLIFERATION. |
-
2001
- 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/en not_active Application Discontinuation
- 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en active IP Right Grant
- 2001-01-29 BR BR0109056-9A patent/BR0109056A/en not_active IP Right Cessation
- 2001-01-29 CN CN01807590A patent/CN1422268A/en active Pending
- 2001-01-29 IL IL15148001A patent/IL151480A0/en unknown
- 2001-01-29 DZ DZ013308A patent/DZ3308A1/en active
- 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
- 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
- 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
- 2001-01-29 HU HU0300136A patent/HUP0300136A2/en unknown
- 2001-01-29 SK SK1247-2002A patent/SK12472002A3/en unknown
- 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/en unknown
- 2001-01-29 JP JP2001568942A patent/JP2003528101A/en not_active Abandoned
- 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
- 2001-01-29 PL PL01358271A patent/PL358271A1/en not_active Application Discontinuation
- 2001-01-29 YU YU66502A patent/YU66502A/en unknown
- 2001-01-29 EA EA200200802A patent/EA200200802A1/en unknown
- 2001-01-29 KR KR1020027011627A patent/KR20020075805A/en not_active Application Discontinuation
- 2001-01-29 EE EEP200200506A patent/EE200200506A/en unknown
- 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
- 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
- 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
- 2001-03-05 AR ARP010101039A patent/AR034119A1/en unknown
- 2001-03-05 SV SV2001000338A patent/SV2001000338A/en not_active Application Discontinuation
- 2001-03-05 CO CO01017398A patent/CO5280200A1/en not_active Application Discontinuation
- 2001-03-05 GT GT200100037A patent/GT200100037A/en unknown
- 2001-03-05 HN HN2001000040A patent/HN2001000040A/en unknown
- 2001-03-05 PE PE2001000216A patent/PE20011177A1/en not_active Application Discontinuation
- 2001-03-05 PA PA20018513201A patent/PA8513201A1/en unknown
-
2002
- 2002-08-23 IS IS6524A patent/IS6524A/en unknown
- 2002-08-23 CR CR6736A patent/CR6736A/en not_active Application Discontinuation
- 2002-09-04 MA MA26801A patent/MA26881A1/en unknown
- 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
- 2002-09-05 NO NO20024235A patent/NO20024235L/en not_active Application Discontinuation
- 2002-10-02 BG BG107161A patent/BG107161A/en unknown
- 2002-10-04 HR HR20020798A patent/HRP20020798A2/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN01036A1 (en) | 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLIN-DEPENDENT AND TYROSINE KINASES | |
| RU2376287C2 (en) | Derivatives of benzamide, method of their production and their application, pharmaceutical composition and method for provision of inhibiting action in respect to hdac | |
| YU73300A (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydro-pyrimidines as inhibitors of cellular proliferation | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| NZ333706A (en) | Benzenesulfone derivatives and medicaments | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| AP2002002479A0 (en) | Pteridinones as kinase inhibitors. | |
| MY118109A (en) | Novel aralkyl amines of spirofuropyridines useful in therapy | |
| CA2677313A1 (en) | Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases | |
| MXPA05013349A (en) | 2-aminopyrimidine derivatives as raf kinase inhibitors. | |
| MY144655A (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| MY116761A (en) | Novel spiroazabicyclic heterocyclic compounds. | |
| SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
| WO2005018557A3 (en) | Substituted pyridinones | |
| PL368409A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments | |
| NZ527249A (en) | Purine derivatives as purinergic receptor antagonists | |
| GEP20043214B (en) | Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same | |
| MXPA04000407A (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents. | |
| ATE401080T1 (en) | (3-((CHINAZOLINE-4-YL)AMINO)-1H-PYRAZOLE-1- YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | |
| MX2020013847A (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof. | |
| MY121793A (en) | 2-phenylpyran-4-one derivatives | |
| ZA9811645B (en) | Acronycine compounds a process for their preparation and pharmaceutical compositions containing them | |
| WO2002087587A3 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors | |
| WO2005019193A3 (en) | Phenylurea derivatives useful in the treatment of conditions mediated by polo-like kinases (plk) | |
| MXPA05011942A (en) | Fused bicyclic-substituted amines as histamine-3 receptor ligands. |